Continuing Enhanced National Surveillance for Prion Diseases in the United States

Closed Posted

Opportunity number
CDC-RFA-CK22-2202
Agency
Applications due
Award size
$3,000,000 to $3,500,000

Opportunity facts

Assistance listings
Funding instrument
Cooperative Agreement
Category
  • Health
Eligible applicants
  • Non-501(c)(3) Nonprofits
  • Tribal Organizations (Not Federally Recognized)
  • Tribal Governments (Federally Recognized)
  • Small Businesses
  • Independent School Districts
  • 501(c)(3) Nonprofits
  • Unrestricted
  • Special District Governments
  • Public or Indian Housing Auth.
  • For Profit Organizations
  • County Governments
  • City/Township Governments
  • Higher Education Inst. (Public)
  • Other
  • Higher Education Inst. (Private)
  • State Governments

Opportunity details come from Grants.gov. Updated .

Synopsis

The Centers for Disease Control and Prevention (CDC) announces the availability of fiscal year (FY) 2022 funds for a cooperative agreement program to continue enhanced national surveillance for human prion diseases in the United States. The purpose of the funding is to continue an active surveillance program similar to that conducted by the National Prion Disease Pathology Surveillance Center (NPDPSC) since 1997 to monitor the occurrence of potentially emerging human transmissible spongiform encephalopathies (TSEs) in the United States. In 1997, in collaboration with the American Association of Neuropathologists (AANP), the National Prion Disease Pathology Surveillance Center was established to enhance national CJD surveillance and to make possible laboratory investigation of newly emerging prion diseases. This pathology center, currently located at Case Western Reserve University in Cleveland, Ohio, provided the services of a cutting edge prion disease laboratory, filling a critical public health gap for monitoring prion diseases in humans. Brain tissues and clinical laboratory information on clinically suspected and diagnosed cases of human prion disease have been evaluated at the NPDPSC for approximately 20 years to confirm diagnoses and determine the type of prion disease, including whether the patients had variant CJD or some other possible emerging prion disease in the United States.

Files

File Type Posted
PUBLISHED Foa_Content_of_CDC-RFA-CK22-2202.pdf PDF

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar grant opportunities
  • Ask GovTribe AI about this opportunity